Related references
Note: Only part of the references are listed.Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
Kavinderjit S. Nanda et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
Fernando S. Velayos et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease
Ingrid Ordas et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis
Lennard Y. W. Lee et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2012)
Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine
Klaus Bendtzen
IMMUNOTHERAPY (2012)
Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease
Gord Blackhouse et al.
JOURNAL OF CROHNS & COLITIS (2012)
Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum
Shui-Long Wang et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2012)
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response
Geert R. D'Haens et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Assessing Response and Loss of Response to Biological Therapies in IBD
Henit Yanai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Guidelines for the management of inflammatory bowel disease in adults
Craig Mowat et al.
GUT (2011)
Practical Application of Anti-TNF Therapy for Luminal Crohn's Disease
Michael A. Kamm et al.
INFLAMMATORY BOWEL DISEASES (2011)
Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease
Casper Steenholdt et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
A. Dignass et al.
JOURNAL OF CROHNS & COLITIS (2010)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Management of Crohn's Disease in Adults
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies
Klaus Bendtzen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2009)
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab
Klaus Bendtzen et al.
ARTHRITIS AND RHEUMATISM (2006)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Mechanisms in failure of infliximab for Crohn's disease
S Nikolaus et al.
LANCET (2000)
Share Paper
